Which company develops and produces Sotoracib (AMG510)?

Sotoracib (AMG 510) was developed by the American biopharmaceutical company Amgen (Amgen). Amgen is a leading global company focused on the field of biotechnology, committed to developing innovative biological drugs to treat major clinical diseases. As a company with strong capabilities and rich experience in the field of cancer treatment, Amgen continues to invest resources and efforts in research and innovation in the field of cancer in order to provide patients with more effective treatment options.

The research and development of sotoracib is based onAmgen's deep accumulation and expertise in tumor biology and molecular targeted therapy. As a targeted drug targeting the KRAS G12C mutation, the development of sotoraxib has gone through long-term scientific exploration and clinical trials, aiming to overcome the treatment problems caused by the KRAS mutation.

Amgen has invested significant resources in the research and development of sotoraxib and is working closely with the clinical medical community to conduct clinical trials to evaluate its efficacy and safety in different cancer types. These efforts eventually made sotorasibu the first KRAS G12C inhibitor approved by the U.S. Food and Drug Administration (FDA), bringing new treatment hope to cancer patients.

Amgencompanies not only develops innovative medicines but also advances medicine and science around the world. Through continuous research and development and innovation, Amgen is committed to providing patients with more and better treatment options and contributing to the progress and development of global cancer treatment.